Easter Holiday 2023 Opening Hours

To help keep our customers informed of changes to our service, we have published our bank holiday opening hours for the 2023 Easter period.

View our bank holiday opening hours:

Easter 2023 Bank Holiday Opening Hours for Pharmacy/Retail customers

Easter 2023 Bank Holiday Opening Hours for Hospital customers

Easter 2023 Bank Holiday Opening Hours for Alcura Homcare Deliveries

Class 4 Caution in use- Methadone 1mg/mL Oral Solution BP Sugar Free and Methadone Mixture 1mg/ml

Thornton & Ross Ltd has informed the MHRA that specific batches of Methadone 1mg/mL Oral Solution BP Sugar Free and Methadone Mixture 1mg/ml, have been packaged with the incorrect Product Information Leaflet (PIL)

MHRA drug alert date: 7th March 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-thornton-and-ross-ltd-methadone-1mg-slash-ml-oral-solution-bp-sugar-free-methadone-mixture-1mg-slash-ml-el-23-a-slash-07?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=5ef47bfe-e5f4-4643-8952-9a5fd54ed360&utm_content=immediately

This is a caution in use only we are not accepting stock returns.

Further Information

For medical information queries please contact thorntonross@medinformation.co.uk. Upon request, Thornton & Ross Ltd will provide hard copies of the updated PIL to pharmacy teams.

Class 2 recall-Levothyroxine 12.5mcg tablets Teva

Reason: “Teva UK Limited is recalling the above batch of Levothyroxine 12.5mcg Tablets in response to a lower than required assay result discovered during routine stability testing.”

MHRA drug alert date  02 March 2023

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-teva-uk-limited-levothyroxine-12-dot-5mcg-tablets-el-23-a-slash-06?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=16a65f83-bc8f-4111-ab4d-5bbfef5ce896&utm_content=immediately

MHRA ref: MDR 226-02/23

Further Information

For any Levothyroxine stock enquiries please contact the Teva UK Limited Customer Solutions team on 0800 590 502.

For more information or medical enquiries, please contact Teva UK Limited by phone on 020 7540 7117 or by email to medinfo@tevauk.com

To report an adverse drug event to Teva UK Limited, please call 020 7540 7337, email uk.safety@tevauk.com or complete the online form at www.tevauk.com/Reporting-side-effects.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 Caution in use- Zestoretic 20/12.5mg tablets

Atnahs Pharma UK has informed the MHRA that the Patient Information Leaflet (PIL) packaged in certain batches of Zestoretic 20mg/12.5mg Tablets contains outdated safety information

MHRA drug alert date: 27th February 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-atnahs-pharma-uk-zestoretic-20mg-slash-12-dot-5mg-tablets-el-23-a-slash-05

This is a caution in use only we are not accepting stock returns.

Further Information

For more information, medical information queries, replacement PIL enquiries and stock control queries, please contact: info@pharmanovia.com

Class 4 Caution in use- Lemsip Max cold and flu capsules

Reckitt Benckiser Healthcare (UK) Limited has informed the MHRA that a typographical error has been identified on the end flap of the outer carton of some batches of Lemsip Max Cold & Flu Capsules.

MHRA drug alert date: 23^rd February 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-reckitt-benckiser-healthcare-uk-limited-lemsip-max-cold-and-flu-capsules-el-23-a-slash-04?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=c26db05c-8d64-472f-a107-53c53ded316e&utm_content=immediately

This is a caution in use only we are not accepting stock returns.

Further Information

For medical information and stock control queries please contact: ConsumerHealth_GB@Reckitt.com and / or 03332005345.

AmerisourceBergen ESG Report FY22

At AmerisourceBergen and Alliance Healthcare, we are united in our purpose to create healthier futures.

When we pursue our purpose, we improve health and well-being, promote a positive social and environmental impact, and inspire our team members. Healthier futures start with the health of our people and planet, which is why we are committed to building partnerships and operations that benefit our stakeholders. 

Visit AmerisourceBergen to see what we have accomplished in fiscal year 2022 (FY22).

On the website, you will also find additional information that has been complied into a series of reports for readers to view. Open the reports to see our comprehensive disclosures, an abridged summary, a quick-hit overview, or highlights related to our DEI efforts.

Stay up to date with all the Alliance Healthcare in the UK ESG news by following our Linked In page here.
 

STOP DISTRIBUTION-EYECEE ONE PRELOADED & EYECEE ONE CRYSTAL PRELOADED INTRAOCULAR LENSES - ALLIANCE DO NOT STOCK

The MHRA is aware of reports of increased intraocular pressure in patients recently implanted with EyeCee One preloaded and EyeCee One Crystal preloaded intraocular lenses (IOLs).

MHRA drug alert date  26 January 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/eyecee-one-preloaded-and-eyecee-one-crystal-preloaded-intraocular-lenses-iols-stop-using-immediately-and-quarantine-all-preloaded-eyecee-one-lenses-dsi-slash-2023-slash-001?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e1e64c23-db14-4853-b96f-0ce8770935db&utm_content=immediately

Alliance do not stock this product and therefore we are not accepting stock returns.

Advice for patients

The advice in this notice is aimed at the healthcare teams who are responsible for providing and monitoring lenses used in cataract surgery. The MHRA is urgently investigating this issue and will be advising healthcare professionals on next steps, including the need to contact patients who may be affected, as soon as more information is available. If you are affected, your healthcare professional will contact you in due course. If you or somebody in your care had cataract surgery recently and are concerned, please contact the hospital where you had surgery for advice.

AmerisourceBergen Announces Intent to Change Name to Cencora

Unified corporate identity reflects the organization’s global reach, impact, and purpose

CONSHOHOCKEN, Pa. (January 24, 2023) – AmerisourceBergen (NYSE: ABC) today announced its intent to change its name to better reflect its bold vision and purpose-driven approach to creating healthier futures. AmerisourceBergen intends to become Cencora. The new name represents a unified presence that will continue to fuel the company’s ongoing growth strategy and advance its impact across healthcare.

“Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care,” said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.

The name Cencora is inspired by customers and team members around the world. In addition, a shared identity will create a more inclusive experience for employees as well as a stronger employer brand to attract talent and increase employee loyalty, retention, and performance. The name tells a compelling story, boldly differentiates the company, and was created with a future-oriented mindset. AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023.

Marie Evans, Managing Director, Alliance Healthcare in the UK said: “Since Alliance Healthcare joined AmerisourceBergen, we have been able to expand, evolve, and innovate on each other’s best-in-class expertise and capabilities across the pharmaceutical supply chain. Aligning under a new brand experience will further enable us to build new services, support healthcare advancements around the world, and deliver quality service for customers even more effectively as one, united organisation. Together, our teams are working with a collective determination to create a meaningful impact across healthcare.”

The change to Cencora is aligned with the organization’s growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain. 

Operating as Cencora, a unified and internationally inclusive name and brand, the company will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform of pharma and biopharma services to support pharmaceutical innovation and access.

For more information, visit: www.cencora.com/uk

CLASS 3 RECALL- LACIDIPINE 4MG TABLETS

Dr Reddy’s Laboratories (UK) Limited is recalling two batches of Lacidipine 4 mg Film-Coated Tablets as a precautionary measure due to the presence of an unknown solvent-like odour.

MHRA drug alert date: 18th January 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-dr-reddys-laboratories-uk-ltd-lacidipine-4-mg-film-coated-tablets-el-23-a-slash-03?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=2e503df5-1891-40b4-a054-1dd7fb232117&utm_content=immediately

Further Information

For medical information enquiries please contact Dr. Reddy’s Laboratories (UK) Ltd Medical Information Department at 01748 828873, or email drreddysGB@EU.ProPharmaGroup.com.

For stock control enquiries please contact Dr. Reddy’s Laboratories (UK) Ltd Customer Services Team at 01482 389858 (or main switchboard at 01482 860228), or email customerserviceuk@drreddys.com.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

It’s been just over a year since we made our sustainability pledge

At Alliance Healthcare, we are united in our responsibility to create healthier futures.

On 1 December 2021, we announced our pledge to become Net Carbon Zero by 2030 (scope 1 and 2). We recognise that there is still much more to do, but a lot of work has been done already across the business in this time to bring us closer to achieving our commitment. 

Our ambition is to be the largest independent sustainable pharmaceutical wholesaler in the UK by 2030. Take a look at our sustainability video to see how far we have come on our journey so far…